|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||16.98 - 17.39|
|52-week range||8.31 - 24.43|
|PE ratio (TTM)||2.52|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.03|
Valeant Pharmaceuticals International Inc. keeps showing up next to the names of struggling investors.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.
According to the terms of the agreement, Kaken Pharmaceutical granted an exclusive license to Valeant Pharmaceuticals for the development and commercialization of products containing KP-470 for the treatment of dermatological and rheumatological disorders in the United States, Canada, Western Europe, and Eastern Europe. In January 2018, Valeant Pharmaceuticals’ subsidiary Bausch & Lomb announced that the European Commission granted a CE mark for the Stellaris Elite vision enhancement system. Nineteen analysts are tracking Valeant Pharmaceuticals in April 2018.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) Xifaxan generated revenues of $275 million, compared to $251 million in 4Q16. That was a 10% growth on a YoY (year-over-year) basis and a 4% decline quarter-over-quarter.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) Wellbutrin generated revenues of $67 million, a 10% growth on a quarter-over-quarter basis. In 4Q17, Wellbutrin’s YoY (year-over-year) growth was flat.
In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.
In 4Q17, Valeant Pharmaceuticals International’s (VRX) U.S Diversified Products generated revenues of $335 million compared to $398 million in 4Q16, a 16% decline on a YoY (year-over-year) basis.
In 4Q17, Soflens, a product of Valeant Pharmaceuticals International’s (VRX) subsidiary Bausch & Lomb, reported revenues of $78 million compared to $79 million in 4Q16. That was a 1% decline on a YoY (year-over-year) basis and a 6% decline quarter-over-quarter.
In 4Q17, Valeant Pharmaceuticals’ (VRX) subsidiary Bausch & Lomb reported revenues of $1.2 billion compared to $1.3 billion in 4Q16. That was a 3% growth on a YoY (year-over-year) basis and a 2% growth quarter-over-quarter.
Valeant Pharmaceuticals (VRX) is bucking the market's slide on Friday, helped by an analyst upgrade. Mizuho's Irina Koffler boosted her rating on the stock to Neutral from Underperform, and raised her price target by $5, to $15. Koffler writes that the move comes as she sees an absence of near-term sell catalysts, and she believes that its can meet its 2018 guidance.
Valeant (VRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
Valeant's (VRX) stock has lost roughly 21% of its value in 2018 despite management's efforts for a turnaround after the turmoil in 2016.
Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.
On February 9, 2018, Teva Pharmaceutical (TEVA) announced the US launch of its generic version of 250 mg Syprine capsules. Syprine capsules are trientine hydrochloride tablets, which are used for the treatment of penicillamine-intolerant patients suffering from Willson’s disease. Willson’s disease is a rare genetic disorder characterized by excessive copper in the body due to the body’s incapability to remove it, which can lead to life-threatening organ damage. According to the National Institute of Health, one in 30,000 people in the United States suffer from Willson’s disease.
Valeant Pharmaceuticals Inc. Chief Executive Joseph Papa received slightly less than $5 million in compensation in 2017, way down from the rewards he received when named to the position in 2016. Papa was ...
Valeant Pharmaceuticals International (VRX) closed higher on Monday, helped by news of its $1.25 billion debt offering, maturing in 2026. Valeant has been on a wild ride lately, seeing its market value triple since bottoming in April 2016. Late last month the specialty-pharma giant lost ground after earnings, but it’s hard to ignore the balance sheet, as Valeant has been trying to shrink the large debt load it took on following an acquisition spree under previous management.